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14 Oral Presentationsa concern is that T cells bearing immunogenic transgenes, such as
those coding for mouse proteins, bacterial selection genes, or viral
suicide genes, would be targeted by the recipient’s immune system
and deleted. We report now that we have reduced the risk of clear-
ance of adoptively transferred genetically modified T cells due to
a host-versus-graft immune-mediated reaction directed to the xeno-
genic components of the CAR and its vector. To decrease immuno-
genicity, we generated a CD19-specific CAR encoded by all-human
transgenes (designated hCAR), wherein the murine CD19-specific
scFv is replaced with a human scFv of a CD19-specific mAb, derived
from mice immunized with CD19 and expressing human immuno-
globulin genes. Primary human T cells were electro-transferred
with the hCAR transgene, using Sleeping Beauty (SB) transposition,
and co-cultured with artificial antigen presenting cells expressing
CD19 antigen and co-stimulatory molecules, resulting in expansion
and stable expression of hCAR without the need for concomitant
drug selection. The hCAR1 T cells could be detected by flow cy-
tometry and Western blot analysis and demonstrated specific lysis
of CD191 tumor targets. This report demonstrates technology
for generating CD19-specific hCAR1 T cells while avoiding ex-
pression of immunogenic proteins (e.g. murine scFv) and will likely
be of interest to the many investigators considering CAR1 T cells
for treatment of tumors.31
COMPREHENSIVE TYPING OF 1143 SINGLE NUCLEOTIDE POLYMOR-
PHISMS (SNP) IN 220 IMMUNOREGULATORY GENES DEMONSTRATES
THAT POLYMORPHISMS IN CCL3, CCL4 AND CCL27 MODULATE THE
RISK OF ACUTE GRAFT VERSUS HOST DISEASE (GVHD)
Mullally, A.1, Kim, H.2, Li, C.2, Mohseni, M.1, Ho, V.1, Alyea, E.P.1,
Antin, J.H.1, Soiffer, R.J.1, Ritz, J.1. 1Dana Farber Cancer Institute,
Boston, MA; 2Dana Farber Cancer Institute, Boston, MA.
A wide range of genetic polymorphisms has been studied in the
context of hematopoietic stem cell transplantation. To date, most
of these analyses have assessed a limited number of arbitrarily cho-
sen SNPs in a single or limited number of genes. We created an Af-
fymetrix custom SNP array and evaluated a total of 1143 SNPs in
220 distinct immune effector genes in 187 hematopoietic stem
cell transplant (HSCT) recipients and their sibling donors. Where
possible, SNPs that have been previously evaluated in the context
of GVHD (e.g. IL-10 SNPs) were included on the array. Genomic
DNA was extracted from peripheral blood mononuclear cells
(PBMC) obtained from patients and their sibling donors. All pa-
tients were in remission at the time of sampling, all had undergone
HSCT at the Dana-Farber Cancer Institute between 1998 and 2005
and all samples were drawn prior to transplantation. The trans-
plants included myeloablative and non-myeloablative conditioning
regimens, T cell depleted (TCD) and non-TCD grafts and sex
matched and sex mis-matched donors. Using dChip software, we
evaluated each of the SNPs on the array in patients and in their do-
nors for an association between genotype and the development of
acute GVHD. Univariate and multivariate statistical analyses were
performed using the Cochran-Mantel-Haenzel test and a logistic
regression model adjusting for age, sex mismatch and other trans-
plant characteristics. The SNPs rs1063340 and rs1634508, that
are believed to regulate the function of CCL3 and CCL4 respec-
tively, were most highly associated with protection against aGVHD
(p\ 0.003), demonstrating an odds ratio (OR) of 0.6 for risk of
acute GVHD in the logistic regression analysis. The SNP
rs11575584, which is thought to regulate CCL27 was most highly
associated with risk of aGVHD (p 5 0.005), with an OR of 2 in
the same logistic regression model. CCL3 and CCL4 are chemo-
kine ligands for CCR5 while CCL27 is a skin-associated chemo-
kine, which interacts with the CCR10 receptor. The CCR5
deletion mutation (which protects against HIV infection) has re-
cently been associated with a reduced risk of aGVHD and increased
epidermal expression of CCL27 has been shown in patients with cu-
taneous aGVHD. This study is the most comprehensive evaluation
to date of functional genetic polymorphisms on the risk of aGVHD.
It suggests that the CCL3-CCL4-CCR5 and CCL27-CCR10 path-
ways play important roles in the pathogenesis of aGVHD and fur-
ther investigation of these pathways is warranted.32
ROLE OF STAT3 SIGNALING IN GVHD AND GVL
Radojcic, V., Pletneva, M.A., Yen, H.-R., Pardoll, D.M., Drake, C.G.,
Luznik, L. Johns Hopkins University.
Growing evidence suggests that STAT3 signaling in CD41 T-
cells plays a key role in the pathogenesis of autoimmunity. We
tested the role of the same pathway in the induction of GVHD
and GVL response in a murine model of alloSCT. Using the
MHC-matched B10.D2/BALB/c model in which GVHD is
CD41 T-cell-mediated and has clinicopathologic features consis-
tent with human chronic sclerodermatous GVHD, we examined
the role of STAT3 signaling in CD41 T-cells in the pathogenesis
of GVHD and GVL response. After conditioning (775 cGy) recip-
ient mice received B10.D2 T-cell depleted (TCD) bone marrow
(BM) and equivalent of 12  106 splenocytes (9.3  106 TCD sple-
nocytes, repleted with 106 wild-type (WT) CD81 and 1.8  106
WT, or CD4-Cre  STAT3flox/flox (STAT3KOCD41) T-cells),
a dose shown to induce all signs of GVHD. We reproducibly in-
duced all signs of chronic GVHD in chimeras receiving WT
CD41 T-cells, but not in chimeras injected with STAT3KOCD41
T-cells (median score of 0.0 vs. 5.2; P\ .001). In situ studies showed
that cutaneous GVHD was accompanied by prominent dermal in-
filtration of donor-derived inflammatory monocytes and complete
turnover to donor CD11c1 epidermal DC chimerism in chimeras
receiving WT but not STAT3KOCD41 T-cells (P\ .001). Splenic
CD11c1DCs, CD41 and CD81T-cell chimerism was nearly com-
pletely donor-derived and did not differ between the two sets of de-
scribed chimeras. We also found that in this model, pathogenic
CD41T-cells do not acquire TH17 phenotype and that STAT3 sig-
naling disruption leads to expansion of Foxp31CD41 T-cells. To
examine the role of STAT3 pathway in eliciting GVL response,
we developed a model of preestablished disease in which 106 A20
lymphoma cells were administered to recipients 10 days prior to al-
loSCT. Addition of GVH inoculum containing STAT3KOCD41
T-cells enabled potent GVL response when compared to animals
receiving only TCD BM, or BM with added TCD SPL (P \
.001). However, it was inferior to that observed in the animals re-
ceiving WT CD41 T-cells (P\ .001). Our findings indicate that:
a) intact STAT3 signaling in CD41 T-cells is required for clinical
manifestations of GVHD in B10.D2/BALB/c model; b) commit-
ment of STAT3KOCD41 T-cells to regulatory Foxp31 lineage is
likely a result of their insensitivity to IL-6 in the abundance of
TGF-b; c) STAT3 ablation enables preservation of GVL, while re-
ducing clinical manifestations of GVHD. Further exploration of the
role of STAT3 pathway in posttransplant events is required.33
SIMILAR GRAFT-VERSUS-LEUKEMIA EFFECT USING MATCHED UNRE-
LATED DONORS, COMPARED TO HLA-IDENTICAL SIBLINGS FOR HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Ringden, O.T.H.1, Pavletic, S.2, Anasetti, C.3, Barrett, J.A.2,
Wang, T.4, Antin, J.H.5, Di Bartolomeo, P.6, Bolwell, B.J.7,
Bredeson, C.8, Cairo, M.S.9, Gale, R.P.10, Giralt, S.11, Hahn, T.12,
Hale, G.A.13, Halter, J.14, Jagasia, M.15, Litzow, M.R.16,
Locatelli, F.17, McCarthy, P.L.12, Cowan, M.J.18, Petersdorf, E.W.19,
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Arora, M.27. 1Karolinska University Hospital Huddinge, Stockholm,
Sweden; 2National Institutes of Health, Bethesda, MD; 3H. Lee Moffitt
Cancer Center & Research Institute, Tampa, FL; 4Medical College of
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9Columbia University Medical Center, New York, NY; 10Center for Ad-
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cisco, CA; 19Fred Hutchinson Cancer Research Center, Seattle, WA;
20Tom Baker Cancer Center, Calgary, Canada; 21UCLA School of
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icine, Chicago, IL; 24University Hospital Utrecht, Utrecht, Netherlands;
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timore, MD; 26University of Florida, HSC College of Medicine, Gaines-
ville, FL; 27University of Minnesota, Minneapolis, MN.
With better matching due to genomic tissue typing and improved
immunosuppression, hematopoietic stem cell transplant (HSCT)
using HLA-matched unrelated donors (URD) have similar outcome
as using HLA-identical sibling donors (sib). Do some leukemia pa-
tients benefit from an URD transplant, because of a stronger graft-
versus-leukemia (GVL) effect? We analyzed the outcome in 941
URD (8/8 HLA-allele matched) transplants, compared to 3158
sib HSCT for acute leukemia (AML and ALL) and chronic myeloid
leukemia (CML) receiving myeloablative conditioning between
1995–2004 and reported to the CIBMTR. Transplant-related mor-
tality (TRM), relapse, survival and leukemia-free-survival (LFS)
were compared for each disease. In a Cox proportional hazard re-
gression model including variables important for outcome, acute
and chronic GVHD were added as time-dependent variables.
Results: Using URD vs. sib HSCT, TRM was increased in early
AML (40% vs. 24%, p5 0.001), and advanced ALL or AML (44%
vs. 31%, p 5 0.01). Among other risk factors, TRM was associated
with URD (p\0.001), advanced disease and increasing donor and
recipient age. Relapse was similar using URD or sib donors; AML
CR1 (5-year relapse 22% vs. 15%), intermediate disease (21% vs.
22%), advanced (43% vs. 46%), ALL early (15% vs. 23%), interme-
diate (36% vs. 32%) and advanced (48% vs. 52%), and for CML
early (5% vs. 6%), intermediate disease (16% vs. 22%) and blast cri-
sis (39% vs. 35%) (ns). In the Cox model, relapse was decreased in
patients with chronic GVHD for AML and ALL and in patients
with acute GVHD for CML. LFS was decreased in AML CR1
and advanced disease, and CML in blast crisis in URD vs. sib trans-
plants. To Conclude: Relapse was the same using URD compared
to sib HSCT, suggesting similar GVL effect. TRM was increased
and LFS was decreased using URD. Therefore, a sib donor should
be the first choice.
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CHARACTERIZATION OF B CELL TARGET ANTIGENS IN PATIENTS WITH
CHRONIC GRAFT VERSUS HOST DISEASE
Sarantopoulos, S.1, Bhuiya, N.S.1, Cutler, C.S.1, Wu, C.J.1,2,
Brusic, V.2, Soiffer, R.J.1, Antin, J.H.1, Ritz, J.1. 1Dana-Farber Cancer
Institute, Boston,MA; 2Dana-Farber Cancer Institute, HarvardMedical
School, Boston, MA.
Patients with chronic graft versus host disease (cGVHD) develop
antibody responses against a variety of target antigens 4–8 months
after hematopoietic stem cell transplantation (HSCT). These anti-
bodies can be specifically directed against amino acid polymor-
phisms that distinguish recipient from donor proteins (allo-
antibodies) or against normal or tumor-associated proteins that
are identical in the recipient and donor (auto-antibodies). We
used high-density protein microarrays (ProtoArray Protein Micro-
arrays V4, Invitrogen) to define the spectrum of antibody targets in
patients with cGVHD after HSCT. These protoarrays contain over
8,000 unique proteins individually spotted on nitrocellulose-coated
slides under native conditions. We used 1-year post-HSCT plasma
from 10 patients with cGVHD for antibody profiling. The reactiv-
ity of each patients cGVHD plasma was compared to a sample ob-
tained from the same patient prior to HSCT as well as to the
patients donor. All 30 arrays were from the same lot and were pro-
cessed by the same operator to enhance consistency. Plasma was
tested at a dilution of 1:500 and results were analyzed using Proto-
Array Prospector software (InVitrogen). Overall, 98 proteins were
targeted by cGVHD plasma and not by any of the pre-HSCT or do-
nor samples. Only 4 of the 98 proteins were targeted by 2 or more
cGVHD patients: protein kinase D3 (nu), ribonucleoprotein auto-
antigen (Ro/SSA), aldehyde dehydrogenase 7, and pyruvate dehy-
drogenase E1 component alpha subunit. Several proteins
identified by cGVHD antibodies were surface membrane or se-
creted proteins. These include PDGFR-alpha, PDGFR-beta,
FGFR-3, FGFR1 oncogene partner, adrenergic-beta receptor ki-
nase, poliovirus-receptor related-3, liprin beta-2, PMEPA1/
STAG1, neuropeptide-Y and serpin peptidase inhibitor. Antibodiesto these targets may have direct activating or inhibitory functional
effects or may initiate lysis of target cells through complement-me-
diated killing or antibody dependent cellular cytotoxicity. These ef-
fects can occur independently of effector T cell responses to these
proteins. These results demonstrate that patients with cGVHD de-
velop antibodies specific for a largely unique spectrum of target an-
tigens. These target antigens include surface membrane and
secreted proteins with potential functional capacities and this may
explain why B cell-directed therapy can improve some clinical man-
ifestations of cGVHD.
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HIGH BAFF AND BCR-ACTIVATED B CELLS IN PATIENTS WITH PRO-
GRESSIVE CHRONIC GRAFT VERSUS HOST DISEASE AFTER RITUXIMAB
TREATMENT
Sarantopoulos, S.1, Stevenson, K.E.2, Kim, H.T.2, Bhuiya, N.S.1,
Cutler, C.S.1, Alyea, E.P.1, Ho, V.T.1, Soiffer, R.J.1, Antin, J.H.1,
Ritz, J.1. 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA.
We recently showed that high levels of B cell Activating Factor
(BAFF) after allogeneic hematopoietic stem cell transplantation
(HSCT) are associated with the development of chronic graft versus
host disease (cGVHD). Clinical responses observed after treatment
with rituximab (anti-CD20) also suggest a role for B cells in the im-
mune pathology of cGVHD, but the effect of rituximab on BAFF
levels and B cell repertoire in patients with cGVHD is unknown.
In patients with autoimmune disease treated with rituximab,
BAFF levels are elevated for 1–2 months after B cell depletion. Since
high BAFF promotes survival and differentiation of human B cell
receptor (BCR)-activated (CD271) B cells into Ig-secreting cells
there is concern that high BAFF after rituximab may contribute
to clinical relapse. We studied 20 patients who received rituximab
(375 mg/m2/week  4 consecutive weeks for one or two cycles)
for steroid-refractory cGVHD. Patients were tested a median of
25 months after starting treatment. At the time of analysis, 9 had
progressive cGVHD, defined as worsening signs or symptoms in
any organ system or the requirement of additional systemic therapy
and 11 had stable or improved cGVHD, measured by reduction in
immune suppression and overall clinical assessment. While median
CD191 B cell number did not differ prior to rituximab treatment
(104.5  106/L versus 203.7  106/L, p 5 0.60, respectively),
CD191B cell number was significantly lower in the 9 patients
with worsening cGVHD at 25 months. Median BAFF levels were
also significantly higher in this group. To examine whether high
BAFF levels affected B cells in these patients, we examined BAFF-
R expression on CD191 B cells by flow cytometry. The median
fluorescence intensity (MFI) of BAFF-R expression was lower in
the progressive disease group compared to the stable/improved
group (0.62 versus 1.67 MFI, respectively). Finally, patients with
progressive cGVHD had increased proportions of CD271 B cells,
indicating that the pool of circulating B cells contains a higher frac-
tion of activated cells in these patients (Table 1). Despite persistent
B lymphopenia after rituximab, patients with progressive cGVHD
had significantly higher BAFF levels associated with a significant in-
crease in the proportion of CD271 BCR-activated circulating B
cells. These data provide a rationale for investigation of BAFF an-
tagonists in the treatment of cGVHD.BAFF levels & B cell phenotype 25 months after rituximab therapy for
cGVHD
Stable/Improved Progressed
(n 5 11) (n 5 9) p-valueTotal B Cell No.
(106)/L124.7 3.8 0.002BAFF (ng/ml) 2.58 7.72 0.01
% BAFF-R on B Cells 68.4 2.2 0.004
% CD27 on B Cells 9.0 70.9 0.04
